The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Roche’s subcutaneous version of Ocrevus (ocrelizumab subcutaneous ) to treat patients with relapsing and primary progressive… read more.
Epidemiologists in Spain have found a new link between childhood sleep patterns and behaviour, with implications for the understanding of attention deficit hyperactivity disorder (ADHD) in preadolescence. The… read more.
The FDA approved Kisunla (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company’s Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD), which… read more.
A drug used to prevent migraine may also be effective in people with migraine who experience rebound headaches, according to a new study published in the June 26,… read more.
Harmony Biosciences announced that the FDA has approved its supplemental New Drug Application (sNDA) for Wakix (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric… read more.
Eisai Co. Ltd. and Biogen Inc. announced that that the FDA has accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: Leqembi) intravenous (IV)… read more.
Depressive symptoms are linked to subsequent memory decline in older people, while poorer memory is also linked to an increase in depressive symptoms later on, according to a… read more.
Targeted blood tests, asking patients about risk factors, and dose modifications can lessen the risk of potentially fatal reactions to antiseizure medications that millions of Americans take for… read more.
When college athletes are evaluated for a possible concussion, the diagnosis is based on an athletic trainer or team physician’s assessment of three things: the player’s symptoms, physical… read more.
New recommendations released in Epileptic Disorders by a global expert group comprising epileptologists, neurologists and pharmacologists from Europe and North America address the critical unmet needs associated with… read more.
Few people in the UK with early stage Alzheimer’s disease are likely to be suitable for the latest drugs which aim to halt progress of the condition, yet… read more.
A new study to be presented at the SLEEP 2024 annual meeting found a distinct relationship between sleep duration, social media usage, and brain activation across brain regions… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
